Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6050117 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL6050257 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL1128201 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL4714660 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL1127353 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL2094922 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL416692 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL6050352 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL1127858 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL416603 | 1.00 | L3MBTL1 (0.30) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022446-A1 | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| EP-2101822-A2 | USE OF PEPTIDES IN COMBINATION WITH SURGICAL INTERVENTION FOR THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2009-09-23 | — | — | EP | claimed |
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2009-08-13 | — | — | US | claimed |
| WO-2008087190-A2 | USE OF PEPTIDES IN COMBINATION WITH SURGICAL INTERVENTION FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | claimed |
| EP-1907010-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2008-04-09 | — | — | EP | claimed |
| WO-2007009894-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-01-25 | — | — | WO | claimed |
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| EP-2539364-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2013-01-02 | — | — | EP | disclosed |
| US-20120021973-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2012-01-26 | — | — | US | disclosed |
| EP-2370104-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011104378-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | WO | disclosed |
| EP-2283037-A1 | PROCESS | Novo Nordisk A/S (DK) | 2011-02-16 | — | — | EP | disclosed |
| US-20100173835-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
| US-5643938-A | RAISING THE ERYTHROPOIETIN LEVEL IN HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0644762-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-29 | — | — | EP | disclosed |
| US-5338743-A | Pancreatitis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-16 | — | — | US | disclosed |
| WO-1993025205-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-12-23 | — | — | WO | disclosed |
| US-5204346-A | Cognition activators; analgesics; antidepressants; vasodilation; cardiovascular and urogential disorders; | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-20 | — | — | US | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| EP-0467248-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021973-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | L3MBTL1 2082/4885 |
| US-20100022446-A1 | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity | MC4R, GIPR, MC3R | L3MBTL1 2467/4885 |
| US-20090203581-A1 | Novel Peptides for Use in the Treatment of Obesity | MC4R, MC3R, GIPR | L3MBTL1 2470/4885 |
| US-20100173835-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | L3MBTL1 2082/4885 |
| US-20130012432-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | L3MBTL1 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.